Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: A review of pharmacokinetics and clinical trial outcomes

Expert Review of Hematology

Volumn 6, Issue 5, 2013, Pages 525-537

  Van Der Jagt, Richard ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

bendamustine; follicular lymphoma; indolent; mantle cell lymphoma; non Hodgkin lymphoma

Indexed keywords

ANTIINFECTIVE AGENT; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ELOTUZUMAB; ETOPOSIDE; IDELALISIB; LENALIDOMIDE; MELPHALAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; APOPTOSIS; ARTHRALGIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; B CELL LYMPHOMA; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CARDIOTOXICITY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; CLINICAL TRIAL (TOPIC); CONSTIPATION; COUGHING; CROSS RESISTANCE; CYTOTOXICITY; DECREASED APPETITE; DIARRHEA; DNA CROSS LINKING; DNA STRAND BREAKAGE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FIRST PASS EFFECT; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; INFUSION RELATED REACTION; INSOMNIA; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SIDE EFFECT; SOLID TUMOR; STOMATITIS; STRESS; THROMBOCYTOPENIA; XEROSTOMIA;

ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, NON-HODGKIN; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; TREATMENT OUTCOME;

EID: 84885914365     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.841538     Document Type: Review

References (56)

1. Swerdlow SH, Campo E, Harris NL et al WHO classification oftumours of haematopoietic and lymphoid tissues, (3rd Edition). WHO Press, Geneva, Switzerland (2008).
2. Cabanillas F. Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm? J. Clin. Oncol. 31, 14-16 (2013).
3. Dreyling M, Buske C, Hiddemann W. Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma. Ann. Oncol. 16 (Suppl. 2), ii99-ii104 (2005).
4. Hiddemann W; European Society for Medical Oncology. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann. Oncol. 14, 1163-1164 (2003).
5. Kahl B. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma. Semin. Hematol. 45, 90-94 (2008).
6. Dreyling M, Thieblemont C, Gallamini A et al. ESMO Consensus conferences: guidelines on malignant lymphoma part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann. Oncol. 24(4), 857-877 (2013)
7. Zelenetz AD. Mantle cell lymphoma: an update on management. Ann. Oncol. 17 (Suppl. 4), iv12-iv14 (2006).
8. Hess G, Smith SM, Berkenblit A, Coiffier B. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin. Oncol. 36 (Suppl. 36), S37-S45 (2009).
9. Koprivnikar JL, Cheson BD. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma. Future Oncol. 8, 359-371 (2012).
10. Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31, 88-94 (2013).
11. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade L ymphoma Study Group. Blood 106, 3725-3732 (2005).
12. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105, 1417-1423 (2005).
13. Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 23, 1984-1992 (2005).
14. Siddhartha G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J. Hematol Oncol. 2, 14 (2009).
15. Kahl BS, Bartlett NL, Leonard JP et al Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 116, 106-114 (2010).
16. Friedberg JW, Cohen P, Chen L et al Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a Phase II multicenter, single-agent study. J. Clin. Oncol. 26, 204-210 (2008).
17. Ghielmini M, Vitolo U, Kimby E et al. ESMO Guidelines consensus conference on malignant lymphoma (2011) part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann. Oncol. 24, 561-576 (2013).
18. MacDonald D, Van der Jagt RH, Burke JM et al. Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): The BRIGHT study. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 31 May-4 June 2013. J Clin Oncol. 31 (15 Suppl.), Abstract 8565 (2013).
19. Leoni LM, Bailey B, Reifert J et al Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res. 14, 309-317 (2008).
20. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin. Oncol. 29, 4-11 (2002).
21. Rasschaert M, Schrijvers D, Van den Brande J et al. A Phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours. Br. J. Cancer 96, 1692-1698 (2007).
22. Owen JS, Melhem M, Passarell JA et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother. Pharmacol. 66, 1039-1049 (2010).
23. Teichert J, Baumann F, Chao Q et al Characterization of two Phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother. Pharmacol. 59, 759-770 (2007).
24. Dubbelman AC, Rosing H, Darwish M et al. Pharmacokinetics and excretion of C-bendamustine in patients with relapsed or refractory malignancy. Drugs R.D. 13(1), 17-28 (2013).
25. Schrijvers D, Vermorken JB. Phase I studies with bendamustine: an update. Semin. Oncol. 29, 15-18 (2002).
26. Schoffski P, Hagedorn T, Grunwald V et al Repeated administration of short infusions of bendamustine: a Phase I study in patients with advanced progressive solid tumours. J. Cancer Res. Clin. Oncol. 126, 41-47 (2000).
27. Schoffski P, Seeland G, Engel H et al. Weekly administration of bendamustine: a Phase I study in patients with advanced progressive solid tumours. Ann. Oncol. 11, 729-734 (2000).
28. Ogura M, Uchida T, Taniwaki M et al. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 101, 2054-2058 (2010).
29. Cheson BD, Wendtner CM, Pieper A et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin. Lymphoma Myeloma Leuk. 10, 21-27 (2010).
30. Knauf WU, Lissichkov T, Aldaoud A et al Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27, 4378-4384 (2009).
31. Fischer K, Cramer P, Busch R et al Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 30, 3209-3216 (2012).
32. Robinson KS, Williams ME, van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J. Clin. Oncol. 26, 4473-4479 (2008).
33. Weide R, Hess G, Koppler H et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter Phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk. Lymphoma 48, 1299-1306 (2007).
34. Friedberg JW, Vose JM, Kelly JL et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 117, 2807-12 (2011).
35. Fowler N, Kahl BS, Lee P et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the Phase II VERTICAL study. J. Clin. Oncol. 29, 3389-3395 (2011).
36. Visco C, Finotto S, Zambello R et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J. Clin. Oncol. 31, 1442-1449 (2013).
37. Herold M, Schulze A, Niederwieser D et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J. Cancer Res. Clin. Oncol. 132, 105-112 (2006).
38. Flinn IW, Van der Jagt RH, Kahl BS et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright Study. Blood 120, Abstract 902 (2012).
39. Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, Phase 3 non-inferiority trial. Lancet 381(9873), 1203-1210 (2013).
40. Flinn IW, Van der Jagt RH, Kahl B et al. Secondary efficacy subanalysis by histology from the Phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL). J. Clin. Oncol. 31(Suppl.), Abstract 8537 (2013).
41. Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 3383-3389 (2005).
42. Hesketh PJ, Batchelor D, Golant M et al. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 12, 543-549 (2004).
43. Burke JM, Van der Jagt RH, Kahl BS et al. Differences in quality of life between bendamustine plus rituximab compared with standard first-line treatments in patients with previously untreated advanced indolent non-Hodgkin's lymphoma or mantle cell lymphoma. Blood 120, Abstract 155 (2012).
44. Treon SP, Hanzis C, Tripsas C et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Clin. Lymphoma Myeloma Leuk. 11, 133-135 (2011).
45. Rummel M, Lerchenmuller C, Greil R et al. Bendamustin-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with Waldenström's macroglobulinemia: results from a prospective, randomized, multicenter study (StiL). Blood 120, Abstract 2739 (2012).
46. Yared J, Kimball A, Baer MR et al. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma. Clin. Lymphoma Myeloma Leuk. 13, 253-257 (2013).
47. Blum KA, Christian B, Flynn JM et al. A Phase I trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Blood 120, Abstract 1643 (2012).
48. Wang M, Gordon L, Rule S et al. A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL). J. Clin. Oncol. 31(Suppl.), Abstract TPS8613 (2013).
49. Merli M, Ferrario A, Basilico C, et al. Novel agents in indolent lymphomas. Ther. Adv. Hematol. 4, 133-48 (2013).
50. Salles GA, Zinzani PL, Jurczak W et al. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). Hematol. Oncol. 1(Suppl.), Abstract 554 (2013).
51. Cheson BD, Crawford JG. A dose-finding study of bendamustine, rituximab and lenalidomide in relapsed and refractory lymphoma. Hematol. Oncol. 1(Suppl.), Abstract 289 (2013).
52. Leonard J, Wagner-Johnston ND, Coutre SE et al. Tolerability and activity of combinations of the PI3Kd inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study. J. Clin. Oncol. 31(Suppl.), Abstract 8500 (2013).
53. Damaj G, Gressin R, Bouabdallah K et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J. Clin. Oncol. 31, 104-110 (2013).
54. Visani G, Malerba L, Stefani PM et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 118, 3419-3425 (2011).
55. Berenson JR, Yellin O, Bessudo A et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 160, 321-3230 (2013).
56. Ponisch W, Mitrou PS, Merkle K et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized Phase III study of the East German Study Group of Hematology and Oncology (OSHO). J. Cancer Res. Clin. Oncol. 132, 205-212 (2006).